These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 18434170

  • 1. Synthesis of 5-chloro-N-aryl-1H-indole-2-carboxamide derivatives as inhibitors of human liver glycogen phosphorylase a.
    Onda K, Suzuki T, Shiraki R, Yonetoku Y, Negoro K, Momose K, Katayama N, Orita M, Yamaguchi T, Ohta M, Tsukamoto S.
    Bioorg Med Chem; 2008 May 15; 16(10):5452-64. PubMed ID: 18434170
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
    Onda K, Shiraki R, Ogiyama T, Yokoyama K, Momose K, Katayama N, Orita M, Yamaguchi T, Furutani M, Hamada N, Takeuchi M, Okada M, Ohta M, Tsukamoto S.
    Bioorg Med Chem; 2008 Dec 01; 16(23):10001-12. PubMed ID: 18952447
    [Abstract] [Full Text] [Related]

  • 3. Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase.
    Hoover DJ, Lefkowitz-Snow S, Burgess-Henry JL, Martin WH, Armento SJ, Stock IA, McPherson RK, Genereux PE, Gibbs EM, Treadway JL.
    J Med Chem; 1998 Jul 30; 41(16):2934-8. PubMed ID: 9685232
    [No Abstract] [Full Text] [Related]

  • 4. Synthesis and pharmacological evaluation of bis-3-(3,4-dichlorophenyl)acrylamide derivatives as glycogen phosphorylase inhibitors.
    Onda K, Shiraki R, Yonetoku Y, Momose K, Katayama N, Orita M, Yamaguchi T, Ohta M, Tsukamoto S.
    Bioorg Med Chem; 2008 Sep 15; 16(18):8627-34. PubMed ID: 18723356
    [Abstract] [Full Text] [Related]

  • 5. Inhibitory mode of indole-2-carboxamide derivatives against HLGPa: molecular docking and 3D-QSAR analyses.
    Liu G, Zhang Z, Luo X, Shen J, Liu H, Shen X, Chen K, Jiang H.
    Bioorg Med Chem; 2004 Aug 01; 12(15):4147-57. PubMed ID: 15246091
    [Abstract] [Full Text] [Related]

  • 6. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes.
    Klabunde T, Wendt KU, Kadereit D, Brachvogel V, Burger HJ, Herling AW, Oikonomakos NG, Kosmopoulou MN, Schmoll D, Sarubbi E, von Roedern E, Schönafinger K, Defossa E.
    J Med Chem; 2005 Oct 06; 48(20):6178-93. PubMed ID: 16190745
    [Abstract] [Full Text] [Related]

  • 7. The effect of glucose on the potency of two distinct glycogen phosphorylase inhibitors.
    Andersen B, Westergaard N.
    Biochem J; 2002 Oct 15; 367(Pt 2):443-50. PubMed ID: 12099891
    [Abstract] [Full Text] [Related]

  • 8. Integrated effects of multiple modulators on human liver glycogen phosphorylase a.
    Ercan-Fang N, Gannon MC, Rath VL, Treadway JL, Taylor MR, Nuttall FQ.
    Am J Physiol Endocrinol Metab; 2002 Jul 15; 283(1):E29-37. PubMed ID: 12067839
    [Abstract] [Full Text] [Related]

  • 9. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo.
    Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, Treadway JL.
    Proc Natl Acad Sci U S A; 1998 Feb 17; 95(4):1776-81. PubMed ID: 9465093
    [Abstract] [Full Text] [Related]

  • 10. Synthesis, in vitro ADME profiling and in vivo pharmacological evaluation of novel glycogen phosphorylase inhibitors.
    Miao GX, Wang YD, Yan ZW, Zhang LY.
    Bioorg Med Chem Lett; 2020 Jul 15; 30(14):127117. PubMed ID: 32527535
    [Abstract] [Full Text] [Related]

  • 11. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
    Kristiansen M, Andersen B, Iversen LF, Westergaard N.
    J Med Chem; 2004 Jul 01; 47(14):3537-45. PubMed ID: 15214781
    [Abstract] [Full Text] [Related]

  • 12. 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
    Wright SW, Rath VL, Genereux PE, Hageman DL, Levy CB, McClure LD, McCoid SC, McPherson RK, Schelhorn TM, Wilder DE, Zavadoski WJ, Gibbs EM, Treadway JL.
    Bioorg Med Chem Lett; 2005 Jan 17; 15(2):459-65. PubMed ID: 15603973
    [Abstract] [Full Text] [Related]

  • 13. Stereoselective synthesis of bioactive isosteviol derivatives as alpha-glucosidase inhibitors.
    Wu Y, Yang JH, Dai GF, Liu CJ, Tian GQ, Ma WY, Tao JC.
    Bioorg Med Chem; 2009 Feb 15; 17(4):1464-73. PubMed ID: 19167896
    [Abstract] [Full Text] [Related]

  • 14. Amino acid anthranilamide derivatives as a new class of glycogen phosphorylase inhibitors.
    Evans KA, Li YH, Coppo FT, Graybill TL, Cichy-Knight M, Patel M, Gale J, Li H, Thrall SH, Tew D, Tavares F, Thomson SA, Weiel JE, Boucheron JA, Clancy DC, Epperly AH, Golden PL.
    Bioorg Med Chem Lett; 2008 Jul 15; 18(14):4068-71. PubMed ID: 18554908
    [Abstract] [Full Text] [Related]

  • 15. Establishment of correlation between in vitro enzyme binding potency and in vivo pharmacological activity: application to liver glycogen phosphorylase a inhibitors.
    Yu LJ, Chen Y, Treadway JL, McPherson RK, McCoid SC, Gibbs EM, Hoover DJ.
    J Pharmacol Exp Ther; 2006 Jun 15; 317(3):1230-7. PubMed ID: 16537796
    [Abstract] [Full Text] [Related]

  • 16. Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316,819 ([R-R*,S*]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide).
    Suh SW, Bergher JP, Anderson CM, Treadway JL, Fosgerau K, Swanson RA.
    J Pharmacol Exp Ther; 2007 Apr 15; 321(1):45-50. PubMed ID: 17251391
    [Abstract] [Full Text] [Related]

  • 17. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG, Somsák L.
    Curr Opin Investig Drugs; 2008 Apr 15; 9(4):379-95. PubMed ID: 18393105
    [Abstract] [Full Text] [Related]

  • 18. FR258900, a novel glycogen phosphorylase inhibitor isolated from Fungus No. 138354. II. Anti-hyperglycemic effects in diabetic animal models.
    Furukawa S, Murakami K, Nishikawa M, Nakayama O, Hino M.
    J Antibiot (Tokyo); 2005 Aug 15; 58(8):503-6. PubMed ID: 16266121
    [Abstract] [Full Text] [Related]

  • 19. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
    Thomson SA, Banker P, Bickett DM, Boucheron JA, Carter HL, Clancy DC, Cooper JP, Dickerson SH, Garrido DM, Nolte RT, Peat AJ, Sheckler LR, Sparks SM, Tavares FX, Wang L, Wang TY, Weiel JE.
    Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1177-82. PubMed ID: 19138846
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and SAR studies of indole-based MK2 inhibitors.
    Xiong Z, Gao DA, Cogan DA, Goldberg DR, Hao MH, Moss N, Pack E, Pargellis C, Skow D, Trieselmann T, Werneburg B, White A.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):1994-9. PubMed ID: 18291646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.